Ideal Therapeutics, a national provider of 340B solutions to healthcare systems, has secured $10.5 million in its latest funding round. This investment marks a significant milestone for the company as it continues to expand its specialized services designed to optimize 340B programs for compliance and financial benefit.
The company specializes in building and managing 340B programs, offering expertise in auditing and program management. Ideal Therapeutics aims to provide healthcare systems with HRSA-compliant methods to maximize their 340B program's potential, benefiting both the entities and their patients. Its Ideal 340B Audits™ are structured to mimic the HRSA audit process, meticulously analyzing programs to identify areas of risk and offering recommendations to eliminate duplicate discounts and diversion.
Additionally, Ideal Therapeutics provides a turnkey Ideal 340B Management™ service. This service involves experienced 340B expert pharmacists who manage all aspects of a 340B program, including internal optimization for covered entities and oversight of 340B vendors and contract pharmacies. The objective is to deliver a solution that lowers costs and enhances compliance for healthcare providers.
This capital infusion is intended to accelerate Ideal Therapeutics' strategic growth initiatives. The company plans to use the funds to expand its service offerings, enhance its technological capabilities, and further scale its operations to meet the growing demand for specialized 340B program management and auditing.
Looking ahead, Ideal Therapeutics is focused on strengthening its market position and continuing to support healthcare systems in navigating the complexities of 340B regulations, ultimately driving greater efficiency and compliance across the industry.
